Company Overview and News

Elementos' Chris Dunks discussed tapping the tin shortfall at Proactive's CEO Sessions

Elementos' (ASX:ELT) executive director, Chris Dunks, joined Proactive's CEO Sessions in Melbourne on Tuesday 25th July and Sydney on Wednesday 26th July.

Argent Minerals underway drilling at Loch Lilly

Argent Minerals (ASX:AGY) has commenced diamond drilling at its Loch Lilly Joint Venture Project located in western New South Wales.

Argent Minerals brings latest from West Wyalong and Kempfield to Melbourne CEO Sessions

Argent Minerals Ltd's (ASX:ARD) CEO, David Busch, will be bringing the company's three-pronged project strategy to the Melbourne leg of Proactive's CEO Sessions.

Tyranna Resources brings gold discovery streak to Proactive's CEO Sessions

Tyranna Resources Ltd (ASX:TYX) has been delivering some bonanza grade results from drilling at the Western Gawler Craton Joint Venture recently, such as: 1 metre at 50.7g/t gold from 71 metres.

Elementos brings tin production timeline to Proactive's CEO Sessions

Elementos Ltd (ASX:ELT) is focused on the wholly-owned Cleveland Tin Project in Tasmania, where it has a clearly defined development strategy.

Elementos raising $2M to advance tin, copper mine in Tasmania.

Elementos (ASX:ELT) is raising up to $2 million from investors to progress the development of its Cleveland tin, copper and tungsten mine in Northwestern Tasmania.

Elementos Ltd to begin survey at Australia’s largest open pit tin resource

The Cleveland project is considered to be the highest grade open pit tin resource within Australia. It contains an indicated resource of 800,000 tonnes at 0.81% tin and 0.27% copper. Elementos is aiming to start production at Cleveland by expanding the open cut resources with a targeted exploration program. The company has contracted a local team to line cut on site in accordance with a plan that has received full approval from Mineral Resource Tasmania.

Quarterly Cashflow Report


Quarterly Activities Report


Half Yearly Accounts


Quarterly Activities Report


Quarterly Cashflow Report


Funding Update


Appendix 3B


Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...